Another phase II study is evaluating the role of PI3K inhibitor copanlisib in combination with fulvestrant in selected ER-positive and/or PgR-positive advanced EOCs and endometrial cancers with PI3K (PIK3CA, PIK3R1) and/or PTEN mutations (NCT05082025). Here, PIK3CA is linked to endometrial cancer.